Insmed Incorporated (0JAV.L)
USD 71.8
(-4.53%)
USD 71.8
(-4.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.2 Billion USD | 2.22% |
| 2022 | 1.17 Billion USD | 92.38% |
| 2021 | 612.26 Million USD | 51.24% |
| 2020 | 404.84 Million USD | 1.97% |
| 2019 | 397.03 Million USD | 25.42% |
| 2018 | 316.55 Million USD | 469.69% |
| 2017 | 55.56 Million USD | 1.42% |
| 2016 | 54.79 Million USD | 117.94% |
| 2015 | 25.14 Million USD | 1.14% |
| 2014 | 24.85 Million USD | 26.27% |
| 2013 | 19.68 Million USD | 1.53% |
| 2012 | 19.38 Million USD | 1511.64% |
| 2011 | 1.2 Million USD | 633.54% |
| 2010 | 164 Thousand USD | -21.15% |
| 2009 | 208 Thousand USD | -90.1% |
| 2008 | 2.1 Million USD | -37.7% |
| 2007 | 3.37 Million USD | 6.74% |
| 2006 | 3.16 Million USD | -50.89% |
| 2005 | 6.43 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.37 Billion USD | 0.63% |
| 2024 Q1 | 1.37 Billion USD | 13.85% |
| 2024 Q3 | 999.86 Million USD | -27.51% |
| 2023 FY | 1.2 Billion USD | 2.22% |
| 2023 Q3 | 1.19 Billion USD | 0.8% |
| 2023 Q2 | 1.18 Billion USD | 0.25% |
| 2023 Q1 | 1.18 Billion USD | 0.58% |
| 2023 Q4 | 1.2 Billion USD | 0.57% |
| 2022 Q2 | 830.56 Million USD | -0.68% |
| 2022 Q4 | 1.17 Billion USD | 41.95% |
| 2022 Q1 | 836.29 Million USD | 36.59% |
| 2022 FY | 1.17 Billion USD | 92.38% |
| 2022 Q3 | 829.77 Million USD | -0.09% |
| 2021 Q1 | 407.59 Million USD | 0.68% |
| 2021 Q3 | 601.2 Million USD | 1.32% |
| 2021 Q4 | 612.26 Million USD | 1.84% |
| 2021 Q2 | 593.35 Million USD | 45.57% |
| 2021 FY | 612.26 Million USD | 51.24% |
| 2020 Q4 | 404.84 Million USD | 1.3% |
| 2020 FY | 404.84 Million USD | 1.97% |
| 2020 Q1 | 398.96 Million USD | 0.48% |
| 2020 Q2 | 398.75 Million USD | -0.05% |
| 2020 Q3 | 399.65 Million USD | 0.22% |
| 2019 FY | 397.03 Million USD | 25.42% |
| 2019 Q1 | 366.38 Million USD | 15.74% |
| 2019 Q2 | 368.84 Million USD | 0.67% |
| 2019 Q4 | 397.03 Million USD | 6.05% |
| 2019 Q3 | 374.4 Million USD | 1.51% |
| 2018 Q2 | 307.15 Million USD | 1.47% |
| 2018 FY | 316.55 Million USD | 469.69% |
| 2018 Q4 | 316.55 Million USD | 1.51% |
| 2018 Q1 | 302.7 Million USD | 444.76% |
| 2018 Q3 | 311.86 Million USD | 1.53% |
| 2017 Q4 | 55.56 Million USD | 0.32% |
| 2017 Q3 | 55.38 Million USD | 0.35% |
| 2017 Q2 | 55.19 Million USD | 0.37% |
| 2017 FY | 55.56 Million USD | 1.42% |
| 2017 Q1 | 54.99 Million USD | 0.37% |
| 2016 Q4 | 54.79 Million USD | 57.99% |
| 2016 FY | 54.79 Million USD | 117.94% |
| 2016 Q1 | 24.78 Million USD | -1.4% |
| 2016 Q2 | 24.82 Million USD | 0.15% |
| 2016 Q3 | 34.68 Million USD | 39.7% |
| 2015 Q4 | 25.14 Million USD | -0.46% |
| 2015 Q1 | 24.98 Million USD | 0.54% |
| 2015 FY | 25.14 Million USD | 1.14% |
| 2015 Q2 | 25.12 Million USD | 0.54% |
| 2015 Q3 | 25.25 Million USD | 0.53% |
| 2014 Q4 | 24.85 Million USD | 24.86% |
| 2014 Q3 | 19.9 Million USD | 0.5% |
| 2014 Q1 | 19.8 Million USD | 0.6% |
| 2014 FY | 24.85 Million USD | 26.27% |
| 2014 Q2 | 19.8 Million USD | 0.02% |
| 2013 FY | 19.68 Million USD | 1.53% |
| 2013 Q1 | 19.51 Million USD | 0.67% |
| 2013 Q2 | 19.64 Million USD | 0.66% |
| 2013 Q4 | 19.68 Million USD | 0.06% |
| 2013 Q3 | 19.67 Million USD | 0.14% |
| 2012 Q3 | 9.28 Million USD | -6.85% |
| 2012 Q2 | 9.96 Million USD | 807.74% |
| 2012 FY | 19.38 Million USD | 1511.64% |
| 2012 Q1 | 1.09 Million USD | -8.73% |
| 2012 Q4 | 19.38 Million USD | 108.83% |
| 2011 Q4 | 1.2 Million USD | 1103.0% |
| 2011 Q3 | 100 Thousand USD | -18.03% |
| 2011 Q2 | 122 Thousand USD | -14.69% |
| 2011 FY | 1.2 Million USD | 633.54% |
| 2011 Q1 | 143 Thousand USD | -12.8% |
| 2010 Q1 | - USD | -100.0% |
| 2010 FY | 164 Thousand USD | -21.15% |
| 2010 Q4 | 164 Thousand USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q3 | 397 Thousand USD | -30.84% |
| 2009 Q2 | 574 Thousand USD | -66.92% |
| 2009 Q1 | 1.73 Million USD | -17.46% |
| 2009 FY | 208 Thousand USD | -90.1% |
| 2009 Q4 | 208 Thousand USD | -47.61% |
| 2008 FY | 2.1 Million USD | -37.7% |
| 2008 Q1 | 3.08 Million USD | -8.68% |
| 2008 Q4 | 2.1 Million USD | -14.1% |
| 2008 Q3 | 2.44 Million USD | -11.76% |
| 2008 Q2 | 2.77 Million USD | -10.0% |
| 2007 Q4 | 3.37 Million USD | -0.5% |
| 2007 FY | 3.37 Million USD | 6.74% |
| 2007 Q1 | 3.23 Million USD | 2.31% |
| 2007 Q2 | 3.31 Million USD | 2.35% |
| 2007 Q3 | 3.39 Million USD | 2.45% |
| 2006 Q3 | 3.62 Million USD | 2.17% |
| 2006 Q4 | 3.16 Million USD | -12.78% |
| 2006 Q2 | 3.54 Million USD | 2.1% |
| 2006 Q1 | 3.47 Million USD | -46.03% |
| 2006 FY | 3.16 Million USD | -50.89% |
| 2005 Q2 | 19.81 Million USD | 6.35% |
| 2005 Q3 | 24.17 Million USD | 22.01% |
| 2005 FY | 6.43 Million USD | 0.0% |
| 2005 Q4 | 6.43 Million USD | -73.37% |
| 2005 Q1 | 18.63 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -3195.363% |
| Dynavax Technologies Corporation | 256.91 Million USD | -368.637% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -2799.304% |
| Perrigo Company plc | 4.07 Billion USD | 70.443% |
| Illumina, Inc. | 2.26 Billion USD | 46.773% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 96.552% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -120299.4% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 87.398% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 91.54% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -592.934% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 55.455% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -4360.889% |
| Waters Corporation | 2.35 Billion USD | 48.886% |
| Biogen Inc. | 7.33 Billion USD | 83.593% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -3059.758% |
| Evolus, Inc. | 126.54 Million USD | -851.428% |
| Adicet Bio, Inc. | 17.7 Million USD | -6701.073% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -2689.154% |
| bluebird bio, Inc. | 330.32 Million USD | -264.487% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -122.572% |
| FibroGen, Inc. | 170.45 Million USD | -606.341% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 55.978% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -5665.086% |
| Homology Medicines, Inc. | 44.05 Million USD | -2632.996% |
| Geron Corporation | 85.89 Million USD | -1301.639% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 49.792% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -170.525% |
| Myriad Genetics, Inc. | 145 Million USD | -730.341% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -95455.079% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -943.811% |
| Zoetis Inc. | 6.8 Billion USD | 82.302% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -27251.068% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 44.459% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -6.184% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -48.935% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -3214.688% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 17.168% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -1980.443% |
| Verastem, Inc. | 41.55 Million USD | -2797.211% |
| Nektar Therapeutics | 230.4 Million USD | -422.565% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -546.017% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -39067.014% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 13.804% |
| OPKO Health, Inc. | 326.56 Million USD | -268.685% |
| Exelixis, Inc. | 189.94 Million USD | -533.868% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -181.044% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -797247.02% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -769.881% |
| Imunon, Inc. | 1.13 Million USD | -105579.048% |
| Blueprint Medicines Corporation | 774.12 Million USD | -55.53% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 19.693% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2012.715% |
| TG Therapeutics, Inc. | 110.79 Million USD | -986.686% |
| Incyte Corporation | 38.28 Million USD | -3044.655% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -37.207% |